IGC Pharma
30 hedge funds and large institutions have $954K invested in IGC Pharma in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
30% more funds holding
Funds holding: 23 → 30 (+7)
0.04% less ownership
Funds ownership: 3.71% → 3.67% (-0.04%)
20% less capital invested
Capital invested by funds: $1.19M → $954K (-$239K)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$47.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.9K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$15.9K |
| 4 |
HF
HRT Financial
New York
|
+$10.4K |
| 5 |
Jane Street
New York
|
+$6.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FW
FullCircle Wealth
Dallas,
Texas
|
-$41.9K |
| 2 |
VF
Virtu Financial
New York
|
-$41.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$14.3K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$4.11K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$3.74K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DFA
26
DHJJ Financial Advisors
Naperville,
Illinois
| $27 | – | – | – |
|
27
Fidelity Investments
Boston,
Massachusetts
| $14 | +$16 | +42 | New |
|
|
EWM
28
Evermay Wealth Management
Arlington,
Virginia
| $11 | +$11 | +30 | New |
|
|
NA
29
NewEdge Advisors
New Orleans,
Louisiana
| $5 | +$5 | +14 | New |
|
|
FW
30
FullCircle Wealth
Dallas,
Texas
| – | -$41.9K | -103,443 | Closed |
|
|
BBA
31
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$3.17K | -10,533 | Closed |
|
32
Simplex Trading
Chicago,
Illinois
| – | -$37 | -100 | -10% |
|
IGC Hedge Fund Activity: Q4 2024 in Review
30 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2024, worth a combined $954K — down 20% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IGC positions and 2 closed out — a net gain of 7 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $47.1K. The largest seller was FullCircle Wealth, exiting entirely with an estimated $41.9K sold.
- 30 institutional investors held IGC Pharma (IGC) as of Q4 2024, up from 23 in Q3 2024.
- Funds reported $954K of IGC Pharma stock for Q4 2024, down 20% quarter-over-quarter.
- 9 funds opened new IGC Pharma positions in Q4 2024 and 2 closed out, a net change of +7 holders.
- The largest IGC Pharma buyer in Q4 2024 was Squarepoint, an estimated $47.1K added.
- The largest IGC Pharma seller in Q4 2024 was FullCircle Wealth, an estimated $41.9K sold.
Based on aggregated 13F filings for Q4 2024.